#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17974	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2176	821.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1510	1510	C	1088	C,A,T	1015,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	32686	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3589	907.0	0	.	n	.	0	T695C	SNP	695	695	T	1036	1036	C	953	C,T,A	912,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	32686	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3589	907.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1678	1678	A	1052	A,G	987,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	32686	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3589	907.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2312	2312	C	1048	C	971	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	32686	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3589	907.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2386	2386	A	1060	A	1005	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	32686	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3589	907.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	2938	2938	C	1016	C	953	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	32686	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3589	907.0	0	HET	.	.	.	A1427G	.	1427	1427	A	1768	1768	A	1152	A,G	837,240	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2118	folP	852	852	100.0	folP.l6.c17.ctg.1	1364	153.7	1	SNP	p	R228S	1	.	.	682	684	AGC	945	947	AGC	227;225;225	A;G;C	214;209;209	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5572	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3555	156.2	1	SNP	p	S91F	0	.	.	271	273	TCC	667	669	TCC	203;201;200	T;C;C	196;194;190	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5572	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3555	156.2	1	SNP	p	D95N	0	.	.	283	285	GAC	679	681	GAC	198;198;198	G;A;C	185;185;186	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5572	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3555	156.2	1	SNP	p	D95G	0	.	.	283	285	GAC	679	681	GAC	198;198;198	G;A;C	185;185;186	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1846	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1321	139.1	1	SNP	p	G45D	0	.	.	133	135	GGC	465	467	GGC	234;233;234	G;G;C	212;214;216	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	948	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1055	89.4	0	.	n	.	0	A197.	DEL	197	197	A	578	578	A	219	A	209	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5974	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2934	202.6	1	SNP	p	D86N	0	.	.	256	258	GAC	602	604	GAC	213;210;215	G;A;C	197;195;202	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5974	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2934	202.6	1	SNP	p	S87R	0	.	.	259	261	AGT	605	607	AGT	214;215;217	A;G;T	202;203;205	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5974	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2934	202.6	1	SNP	p	S87W	0	.	.	259	261	AGT	605	607	AGT	214;215;217	A;G;T	202;203;205	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5974	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2934	202.6	1	SNP	p	S87I	0	.	.	259	261	AGT	605	607	AGT	214;215;217	A;G;T	202;203;205	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5974	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2934	202.6	1	SNP	p	S88P	0	.	.	262	264	TCC	608	610	TCC	217;216;215	T;C;C	204;202;203	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4872	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2655	182.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1541	1543	GGC	244;241;240	G;G;C	221;219;214	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4536	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	185.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1296	1298	GCA	219;219;221	G;C;A	205;202;210	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4536	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	185.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1299	1301	ATC	221;218;221	A;T;C	209;202;207	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4536	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	185.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1311	1313	GTG	219;218;223	G;T;G	208;202;208	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4536	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	185.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1311	1313	GTG	219;218;223	G;T;G	208;202;208	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4536	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	185.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1815	1817	ACC	199;201;203	A;C;C	186;190;193	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4536	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	185.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1869	1871	GCG	204;202;204	G;C,G;G	183;164,1;176	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4536	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	185.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1869	1871	GCG	204;202;204	G;C,G;G	183;164,1;176	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4536	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	185.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1992	1994	GGC	180;178;177	G;G;C	165;163;160	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4536	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	185.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2001	2003	GGC	171;168;168	G;G;C	154;151;155	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4536	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2434	185.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2019	2021	CCG	143;144;140	C,G;C;G	112,6;113;108	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6530	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3218	202.2	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1733	1735	CTG	204;205;209	C;T;G	189;189;194	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2622	porA	1146	1146	99.83	porA.l6.c4.ctg.1	1785	146.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	502	502	C	181	C	171	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	E48G	NONSYN	142	144	GAA	355	357	GGA	259;258;260	G;G,A;A	245;242,1;245	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	F135L	NONSYN	403	405	TTT	616	618	CTT	236;237;237	C;T;T	220;222;222	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	R143G	NONSYN	427	429	AGA	640	642	GGA	232;231;234	G;G;A	218;219;218	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	G189S	NONSYN	565	567	GGC	778	780	AGC	243;243;243	A;G;C	233;231;231	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	.	MULTIPLE	619	621	AAA	832	837	TACTAC	238;238;237;236;237;236	T;A;C;T;A;C	223;221;222;221;221;224	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	K208M	NONSYN	622	624	AAA	839	841	ATG	236;241;243	A;T;G	225;230;234	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	.	MULTIPLE	628	630	GAA	845	848	AAAC	244;247;248;251	A;A;A;C	235;238;240;243	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	N212Y	NONSYN	634	636	AAT	853	855	TAT	245;246;247	T;A;T	236;240;241	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	I214M	NONSYN	640	642	ATC	859	861	ATG	245;247;247	A;T;G	239;241;239	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	L218F	NONSYN	652	654	CTT	871	873	TTT	260;263;263	T;T;T	248;252;253	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	A238V	NONSYN	712	714	GCC	931	933	GTT	267;268;268	G;T;T	250;249;249	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	T252A	NONSYN	754	756	ACA	973	975	GCA	261;258;261	G;C;A	251;247;253	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	W253T	NONSYN	757	759	TGG	976	978	ACG	259;256;256	A;C;G	250;246;247	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	S254R	NONSYN	760	762	AGT	979	981	AGG	258;256;258	A;G;G	249;246;246	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	A255V	NONSYN	763	765	GCT	982	984	GTT	258;258;262	G;T;T	245;239;251	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	L275V	NONSYN	823	825	TTA	1042	1044	GTA	270;269;267	G;T;A	256;256;254	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	S288T	NONSYN	862	864	TCT	1081	1083	ACT	289;289;289	A;C;T	271;274;274	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	H290D	NONSYN	868	870	CAT	1087	1089	GAT	286;282;281	G;A;T	269;264;266	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	S291D	NONSYN	871	873	AGT	1090	1092	GAT	283;277;278	G;A;T	267;263;263	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	D293N	NONSYN	877	879	GAC	1096	1098	AAC	269;270;272	A;A;C	259;257;259	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	Y294H	NONSYN	880	882	TAC	1099	1101	CAC	270;270;274	C;A;C	255;256;259	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	0	.	p	.	0	E329D	NONSYN	985	987	GAA	1204	1206	GAC	302;300;300	G;A;C	282;275;280	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	1	SNP	p	G120K	0	.	.	358	360	GGT	571	573	GGT	225;221;222	G;G;T	210;210;201	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	1	SNP	p	A121N	0	.	.	361	363	GCC	574	576	GCC	223;223;225	G;C;C	208;211;209	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3316	porB1b	1035	1035	96.45	porB1b.l15.c30.ctg.1	1419	230.7	1	SNP	p	A121D	0	.	.	361	363	GCC	574	576	GCC	223;223;225	G;C;C	208;211;209	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12796	rpoB	4179	4179	100.0	rpoB.l6.c30.ctg.1	4877	261.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2007	2009	AAT	256;257;259	A;A;T	246;244;244	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1384	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1190	115.9	1	SNP	p	V57M	1	.	.	169	171	ATG	620	622	ATG	277;280;279	A;T;G	262;263;261	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
